Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) are U.S. federal grant programs that fund early-stage R&D at small businesses. NIH, NSF, DoD, and BARDA are the most relevant agencies for MedTech. Phase I (~$300K) funds feasibility; Phase II (~$2M) funds prototype and validation. Award amounts and topics are set by each agency and published in its solicitations, so the figures above are typical rather than fixed. STTR also requires a formal partnership with a research institution.

Why it matters

Non-dilutive, retains IP with the small business, and signals scientific credibility. Highly competitive; success rates around 15–20% for NIH.

Common pitfalls

•A common pitfall is misunderstanding that securing an SBIR/STTR grant automatically confers regulatory approval or streamlines the regulatory submission process.
•Another mistake is neglecting to integrate regulatory strategy and quality system considerations early in the R&D process, even during the grant-funded phases.
•Companies often fail to allocate sufficient grant funds and resources specifically for crucial regulatory activities, such as biocompatibility testing or electromagnetic compatibility (EMC) testing, which are necessary for eventual market authorization.
•Assuming that the technical success criteria for a grant are the same as the regulatory requirements for market clearance or approval can lead to significant delays.
•Mismanaging intellectual property generated during the grant project can create future regulatory and commercial challenges, despite the grants’ general policy of retaining IP with the small business.

Sources

SBIR.gov · SBIR.gov
NIH SEED · NIH
NVCA Model Documents · NVCA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.